ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2026
Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases.
Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Renal cell carcinoma with fibromyomatous stroma and renal hemangioblastoma represent a continuum of one tumor spectrum: a comprehensive, critical review of the literature.Virchows Archiv : an international journal of pathology · 2026Review
- Renal hemangioblastoma mimicking clear cell renal cell carcinoma: a case report emphasizing contrast-enhanced ultrasound findings.BMC nephrology · 2026Article
- Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Hemangioblastoma (HB) is a benign central nervous system (CNS) tumor associated with mutations in the von Hippel-Lindau (VHL) gene. Although rare outside the CNS, the pathological and genetic features remain poorly understood. We analyzed four renal hemangioblastomas (RHB). Demographics, clinical presentation, and follow-up data were collected. After assessing hematoxylin and eosin-stained slides, immunophenotyping was conducted using CA9, α-inhibin, AE1/AE3, CD10, CD56, PAX8, S100, MelanA, HMB45, CD117, FH, SDHB, and brachyury antibodies, alongside mismatch repair (MMR) deficiency examination. Additionally, whole-exome sequencing (WES) was performed in 3 tumors. Our cohort comprised 3 male and 1 female patients, with a median age of 49 years. No data on VHL disease were available. Well-circumscribed tumors (median size: 25.5 mm) displayed clear vacuolated cytoplasm with a vascular component. Immunostaining revealed expression of PAX8, α-inhibin, AE1/AE3, S100, and cytoplasmic brachyury. WES analysis detected no pathogenic mutations. No cancer-related deaths or progressions were observed. Histologically, RHB resembles low-grade ccRCC and shares expression of PAX8, pancytokeratin, and CA9. However, RHB is uniquely positive for α-inhibin, S100, and lacks VHL alterations. Its favorable prognosis underscores the importance of distinguishing it from ccRCC to prevent unnecessary treatments. Further research is warranted to elucidate the underlying genetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.